EyeBio is a clinical-stage biotechnology company focused on developing innovative therapies for eye diseases, particularly those that threaten vision. The company's lead asset, Restoret™, is a tri-specific Wnt agonist antibody designed to address retinal diseases such as diabetic macular edema (DME) and neovascular age-related macular degeneration (nvAMD). By targeting the Wnt signaling pathway, Restoret aims to restore and maintain the blood-retinal barrier, which is crucial for preventing vascular leakage—a common issue in various retinal conditions. The company has successfully completed initial phases of clinical trials, demonstrating favorable safety and tolerability, and is preparing for pivotal studies to further evaluate Restoret's efficacy.

Founded in 2021 by experienced ophthalmology leaders Dr. David Guyer and Dr. Anthony P. Adamis, EyeBio has rapidly built a robust pipeline of therapies through strategic partnerships and significant funding, including a recent expansion of its Series A financing to $130 million. The leadership team, which includes experts with extensive backgrounds in drug development and clinical trials, is committed to addressing unmet medical needs in ophthalmology. EyeBio's innovative approach and focus on multi-specific antibodies position it to potentially redefine treatment standards for patients suffering from serious eye diseases.

United States

EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.

EyeBio

Company Details